real-time news and commentary for investors
Monday, Dec 10
2012, 2:08 PM
Alnylam Pharmaceuticals (ALNY +5.2%) trades up after reporting encouraging pre-clinical data for...
Alnylam Pharmaceuticals (ALNY +5.2%) trades up after reporting encouraging pre-clinical data for its RNAi therapeutic program to treat of hemophilia and other bleeding disorders. The drug candidate produced up to a four-fold increase in thrombin - a protein that plays a role in blood coagulation - in testing with non-human primates. The company says it eventually plans to have five different medications in clinical development by the end of 2015.